

Global Chemotherapy-induced Nausea and Vomiting Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028

<https://marketpublishers.com/r/G73691F5A5A3EN.html>

Date: June 2022

Pages: 110

Price: US\$ 3,480.00 (Single User License)

ID: G73691F5A5A3EN

Abstracts

The Chemotherapy-induced Nausea and Vomiting Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Chemotherapy-induced Nausea and Vomiting Treatment market size is estimated to be worth US\$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Acute Nausea and Vomiting Treatment accounting for % of the Chemotherapy-induced Nausea and Vomiting Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Aloxi (Palonosetron) segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Chemotherapy-induced Nausea and Vomiting Treatment include GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co, and Tesaro, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Chemotherapy-induced Nausea and Vomiting Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can

help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Aloxi (Palonosetron)

Kytril (Granisetron)

Emend (Aprepitant)

Others

Market segment by Application, can be divided into

Acute Nausea and Vomitting Treatment

Delayed Nausea and Vomitting Treatment

Anticipatory Nausea and Vomitting Treatment

Market segment by players, this report covers

GlaxoSmithKline

Helsinn

Heron Therapeutics

Merck & Co

Tesaro

Acacia Pharma

Aphios

Barr Laboratories

Baxter Healthcare

Eisai

Especificos Stendhal

F.Hoffmann La Roche

Mundipharma

Mylan Pharmaceuticals

OPKO Health

Orchid Healthcare

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Chemotherapy-induced Nausea and Vomiting Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Chemotherapy-induced Nausea and Vomiting

Treatment, with revenue, gross margin and global market share of Chemotherapy-induced Nausea and Vomiting Treatment from 2019 to 2022.

Chapter 3, the Chemotherapy-induced Nausea and Vomiting Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022. and Chemotherapy-induced Nausea and Vomiting Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Chemotherapy-induced Nausea and Vomiting Treatment research findings and conclusion, appendix and data source.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Chemotherapy-induced Nausea and Vomiting Treatment

1.2 Classification of Chemotherapy-induced Nausea and Vomiting Treatment by Type

1.2.1 Overview: Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Type in 2021

1.2.3 Aloxi (Palonosetron)

1.2.4 Kytril (Granisetron)

1.2.5 Emend (Aprepitant)

1.2.6 Others

1.3 Global Chemotherapy-induced Nausea and Vomiting Treatment Market by Application

1.3.1 Overview: Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Acute Nausea and Vomiting Treatment

1.3.3 Delayed Nausea and Vomiting Treatment

1.3.4 Anticipatory Nausea and Vomiting Treatment

1.4 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size & Forecast

1.5 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast by Region

1.5.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region, (2017-2022)

1.5.3 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Prospect (2017-2028)

1.5.4 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Prospect (2017-2028)

1.5.6 South America Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Chemotherapy-induced Nausea and Vomiting

Treatment Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Chemotherapy-induced Nausea and Vomiting Treatment Market Drivers

1.6.2 Chemotherapy-induced Nausea and Vomiting Treatment Market Restraints

1.6.3 Chemotherapy-induced Nausea and Vomiting Treatment Trends Analysis

2 COMPANY PROFILES

2.1 GlaxoSmithKline

2.1.1 GlaxoSmithKline Details

2.1.2 GlaxoSmithKline Major Business

2.1.3 GlaxoSmithKline Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.1.4 GlaxoSmithKline Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 GlaxoSmithKline Recent Developments and Future Plans

2.2 Helsinn

2.2.1 Helsinn Details

2.2.2 Helsinn Major Business

2.2.3 Helsinn Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.2.4 Helsinn Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Helsinn Recent Developments and Future Plans

2.3 Heron Therapeutics

2.3.1 Heron Therapeutics Details

2.3.2 Heron Therapeutics Major Business

2.3.3 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.3.4 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Heron Therapeutics Recent Developments and Future Plans

2.4 Merck & Co

2.4.1 Merck & Co Details

2.4.2 Merck & Co Major Business

2.4.3 Merck & Co Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.4.4 Merck & Co Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

- 2.4.5 Merck & Co Recent Developments and Future Plans
- 2.5 Tesaro
 - 2.5.1 Tesaro Details
 - 2.5.2 Tesaro Major Business
 - 2.5.3 Tesaro Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions
 - 2.5.4 Tesaro Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
 - 2.5.5 Tesaro Recent Developments and Future Plans
- 2.6 Acacia Pharma
 - 2.6.1 Acacia Pharma Details
 - 2.6.2 Acacia Pharma Major Business
 - 2.6.3 Acacia Pharma Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions
 - 2.6.4 Acacia Pharma Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
 - 2.6.5 Acacia Pharma Recent Developments and Future Plans
- 2.7 Aphios
 - 2.7.1 Aphios Details
 - 2.7.2 Aphios Major Business
 - 2.7.3 Aphios Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions
 - 2.7.4 Aphios Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
 - 2.7.5 Aphios Recent Developments and Future Plans
- 2.8 Barr Laboratories
 - 2.8.1 Barr Laboratories Details
 - 2.8.2 Barr Laboratories Major Business
 - 2.8.3 Barr Laboratories Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions
 - 2.8.4 Barr Laboratories Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
 - 2.8.5 Barr Laboratories Recent Developments and Future Plans
- 2.9 Baxter Healthcare
 - 2.9.1 Baxter Healthcare Details
 - 2.9.2 Baxter Healthcare Major Business
 - 2.9.3 Baxter Healthcare Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions
 - 2.9.4 Baxter Healthcare Chemotherapy-induced Nausea and Vomiting Treatment

Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Baxter Healthcare Recent Developments and Future Plans

2.10 Eisai

2.10.1 Eisai Details

2.10.2 Eisai Major Business

2.10.3 Eisai Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.10.4 Eisai Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Eisai Recent Developments and Future Plans

2.11 Especificos Stendhal

2.11.1 Especificos Stendhal Details

2.11.2 Especificos Stendhal Major Business

2.11.3 Especificos Stendhal Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.11.4 Especificos Stendhal Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Especificos Stendhal Recent Developments and Future Plans

2.12 F.Hoffmann La Roche

2.12.1 F.Hoffmann La Roche Details

2.12.2 F.Hoffmann La Roche Major Business

2.12.3 F.Hoffmann La Roche Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.12.4 F.Hoffmann La Roche Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 F.Hoffmann La Roche Recent Developments and Future Plans

2.13 Mundipharma

2.13.1 Mundipharma Details

2.13.2 Mundipharma Major Business

2.13.3 Mundipharma Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.13.4 Mundipharma Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Mundipharma Recent Developments and Future Plans

2.14 Mylan Pharmaceuticals

2.14.1 Mylan Pharmaceuticals Details

2.14.2 Mylan Pharmaceuticals Major Business

2.14.3 Mylan Pharmaceuticals Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.14.4 Mylan Pharmaceuticals Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Mylan Pharmaceuticals Recent Developments and Future Plans

2.15 OPKO Health

2.15.1 OPKO Health Details

2.15.2 OPKO Health Major Business

2.15.3 OPKO Health Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.15.4 OPKO Health Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 OPKO Health Recent Developments and Future Plans

2.16 Orchid Healthcare

2.16.1 Orchid Healthcare Details

2.16.2 Orchid Healthcare Major Business

2.16.3 Orchid Healthcare Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

2.16.4 Orchid Healthcare Chemotherapy-induced Nausea and Vomiting Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Orchid Healthcare Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Chemotherapy-induced Nausea and Vomiting Treatment Players Market Share in 2021

3.2.2 Top 10 Chemotherapy-induced Nausea and Vomiting Treatment Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Chemotherapy-induced Nausea and Vomiting Treatment Players Head Office, Products and Services Provided

3.4 Chemotherapy-induced Nausea and Vomiting Treatment Mergers & Acquisitions

3.5 Chemotherapy-induced Nausea and Vomiting Treatment New Entrants and Expansion Plans

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue and

Market Share by Type (2017-2022)

4.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Forecast by Type (2023-2028)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Application (2017-2022)

5.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Forecast by Application (2023-2028)

6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION

6.1 North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type (2017-2028)

6.2 North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2017-2028)

6.3 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country

6.3.1 North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Country (2017-2028)

6.3.2 United States Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

6.3.3 Canada Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

6.3.4 Mexico Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION

7.1 Europe Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type (2017-2028)

7.2 Europe Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2017-2028)

7.3 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country

7.3.1 Europe Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Country (2017-2028)

7.3.2 Germany Chemotherapy-induced Nausea and Vomiting Treatment Market Size

and Forecast (2017-2028)

7.3.3 France Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

7.3.5 Russia Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

7.3.6 Italy Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION

8.1 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type (2017-2028)

8.2 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2017-2028)

8.3 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region

8.3.1 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Region (2017-2028)

8.3.2 China Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

8.3.3 Japan Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

8.3.4 South Korea Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

8.3.5 India Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

8.3.7 Australia Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION

9.1 South America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type (2017-2028)

9.2 South America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2017-2028)

9.3 South America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country

9.3.1 South America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Country (2017-2028)

9.3.2 Brazil Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

9.3.3 Argentina Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION

10.1 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type (2017-2028)

10.2 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2017-2028)

10.3 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country

10.3.1 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Country (2017-2028)

10.3.2 Turkey Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

10.3.4 UAE Chemotherapy-induced Nausea and Vomiting Treatment Market Size and Forecast (2017-2028)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Chemotherapy-induced Nausea and Vomiting Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million) by Region (2017-2022)

Table 5. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Region (2023-2028)

Table 6. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 7. GlaxoSmithKline Major Business

Table 8. GlaxoSmithKline Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 9. GlaxoSmithKline Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Helsinn Corporate Information, Head Office, and Major Competitors

Table 11. Helsinn Major Business

Table 12. Helsinn Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 13. Helsinn Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Heron Therapeutics Corporate Information, Head Office, and Major Competitors

Table 15. Heron Therapeutics Major Business

Table 16. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 17. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Merck & Co Corporate Information, Head Office, and Major Competitors

Table 19. Merck & Co Major Business

Table 20. Merck & Co Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 21. Merck & Co Chemotherapy-induced Nausea and Vomiting Treatment

Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Tesaro Corporate Information, Head Office, and Major Competitors

Table 23. Tesaro Major Business

Table 24. Tesaro Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 25. Tesaro Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Acacia Pharma Corporate Information, Head Office, and Major Competitors

Table 27. Acacia Pharma Major Business

Table 28. Acacia Pharma Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 29. Acacia Pharma Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Aphios Corporate Information, Head Office, and Major Competitors

Table 31. Aphios Major Business

Table 32. Aphios Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 33. Aphios Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Barr Laboratories Corporate Information, Head Office, and Major Competitors

Table 35. Barr Laboratories Major Business

Table 36. Barr Laboratories Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 37. Barr Laboratories Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Baxter Healthcare Corporate Information, Head Office, and Major Competitors

Table 39. Baxter Healthcare Major Business

Table 40. Baxter Healthcare Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 41. Baxter Healthcare Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Eisai Corporate Information, Head Office, and Major Competitors

Table 43. Eisai Major Business

Table 44. Eisai Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 45. Eisai Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Especificos Stendhal Corporate Information, Head Office, and Major Competitors

Table 47. Especificos Stendhal Major Business

Table 48. Especificos Stendhal Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 49. Especificos Stendhal Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. F.Hoffmann La Roche Corporate Information, Head Office, and Major Competitors

Table 51. F.Hoffmann La Roche Major Business

Table 52. F.Hoffmann La Roche Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 53. F.Hoffmann La Roche Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Mundipharma Corporate Information, Head Office, and Major Competitors

Table 55. Mundipharma Major Business

Table 56. Mundipharma Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 57. Mundipharma Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Mylan Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 59. Mylan Pharmaceuticals Major Business

Table 60. Mylan Pharmaceuticals Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 61. Mylan Pharmaceuticals Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. OPKO Health Corporate Information, Head Office, and Major Competitors

Table 63. OPKO Health Major Business

Table 64. OPKO Health Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 65. OPKO Health Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Orchid Healthcare Corporate Information, Head Office, and Major Competitors

Table 67. Orchid Healthcare Major Business

Table 68. Orchid Healthcare Chemotherapy-induced Nausea and Vomiting Treatment Product and Solutions

Table 69. Orchid Healthcare Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 71. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 72. Breakdown of Chemotherapy-induced Nausea and Vomiting Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 73. Chemotherapy-induced Nausea and Vomiting Treatment Players Head Office, Products and Services Provided

Table 74. Chemotherapy-induced Nausea and Vomiting Treatment Mergers & Acquisitions in the Past Five Years

Table 75. Chemotherapy-induced Nausea and Vomiting Treatment New Entrants and Expansion Plans

Table 76. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million) by Type (2017-2022)

Table 77. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Share by Type (2017-2022)

Table 78. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Forecast by Type (2023-2028)

Table 79. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2017-2022)

Table 80. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Forecast by Application (2023-2028)

Table 81. North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type (2017-2022) & (USD Million)

Table 82. North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type (2023-2028) & (USD Million)

Table 83. North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2017-2022) & (USD Million)

Table 84. North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2023-2028) & (USD Million)

Table 85. North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Country (2017-2022) & (USD Million)

Table 86. North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Country (2023-2028) & (USD Million)

Table 87. Europe Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Type (2017-2022) & (USD Million)

Table 88. Europe Chemotherapy-induced Nausea and Vomiting Treatment Revenue

by Type (2023-2028) & (USD Million)

Table 89. Europe Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Application (2017-2022) & (USD Million)

Table 90. Europe Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Application (2023-2028) & (USD Million)

Table 91. Europe Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Country (2017-2022) & (USD Million)

Table 92. Europe Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Country (2023-2028) & (USD Million)

Table 93. Asia-Pacific Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Type (2017-2022) & (USD Million)

Table 94. Asia-Pacific Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Type (2023-2028) & (USD Million)

Table 95. Asia-Pacific Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Application (2017-2022) & (USD Million)

Table 96. Asia-Pacific Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Application (2023-2028) & (USD Million)

Table 97. Asia-Pacific Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Region (2017-2022) & (USD Million)

Table 98. Asia-Pacific Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Region (2023-2028) & (USD Million)

Table 99. South America Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Type (2017-2022) & (USD Million)

Table 100. South America Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Type (2023-2028) & (USD Million)

Table 101. South America Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Application (2017-2022) & (USD Million)

Table 102. South America Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Application (2023-2028) & (USD Million)

Table 103. South America Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Country (2017-2022) & (USD Million)

Table 104. South America Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Country (2023-2028) & (USD Million)

Table 105. Middle East & Africa Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Type (2017-2022) & (USD Million)

Table 106. Middle East & Africa Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Type (2023-2028) & (USD Million)

Table 107. Middle East & Africa Chemotherapy-induced Nausea and Vomitting Treatment Revenue by Application (2017-2022) & (USD Million)

Table 108. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Application (2023-2028) & (USD Million)

Table 109. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Country (2017-2022) & (USD Million)

Table 110. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Country (2023-2028) & (USD Million)

List Of Figures

LIST OF FIGURES

- Figure 1. Chemotherapy-induced Nausea and Vomiting Treatment Picture
- Figure 2. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Type in 2021
- Figure 3. Aloxi (Palonosetron)
- Figure 4. Kytril (Granisetron)
- Figure 5. Emend (Aprepitant)
- Figure 6. Others
- Figure 7. Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Application in 2021
- Figure 8. Acute Nausea and Vomiting Treatment Picture
- Figure 9. Delayed Nausea and Vomiting Treatment Picture
- Figure 10. Anticipatory Nausea and Vomiting Treatment Picture
- Figure 11. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
- Figure 12. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Forecast (2017-2028) & (USD Million)
- Figure 13. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Region (2017-2028)
- Figure 14. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Region in 2021
- Figure 15. North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million) and Growth Rate (2017-2028)
- Figure 16. Europe Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million) and Growth Rate (2017-2028)
- Figure 17. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million) and Growth Rate (2017-2028)
- Figure 18. South America Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million) and Growth Rate (2017-2028)
- Figure 19. Middle East and Africa Chemotherapy-induced Nausea and Vomiting Treatment Revenue (USD Million) and Growth Rate (2017-2028)
- Figure 20. Chemotherapy-induced Nausea and Vomiting Treatment Market Drivers
- Figure 21. Chemotherapy-induced Nausea and Vomiting Treatment Market Restraints
- Figure 22. Chemotherapy-induced Nausea and Vomiting Treatment Market Trends
- Figure 23. GlaxoSmithKline Recent Developments and Future Plans
- Figure 24. Helsinn Recent Developments and Future Plans

- Figure 25. Heron Therapeutics Recent Developments and Future Plans
- Figure 26. Merck & Co Recent Developments and Future Plans
- Figure 27. Tesaro Recent Developments and Future Plans
- Figure 28. Acacia Pharma Recent Developments and Future Plans
- Figure 29. Aphios Recent Developments and Future Plans
- Figure 30. Barr Laboratories Recent Developments and Future Plans
- Figure 31. Baxter Healthcare Recent Developments and Future Plans
- Figure 32. Eisai Recent Developments and Future Plans
- Figure 33. Especificos Stendhal Recent Developments and Future Plans
- Figure 34. F.Hoffmann La Roche Recent Developments and Future Plans
- Figure 35. Mundipharma Recent Developments and Future Plans
- Figure 36. Mylan Pharmaceuticals Recent Developments and Future Plans
- Figure 37. OPKO Health Recent Developments and Future Plans
- Figure 38. Orchid Healthcare Recent Developments and Future Plans
- Figure 39. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Share by Players in 2021
- Figure 40. Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
- Figure 41. Global Top 3 Players Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share in 2021
- Figure 42. Global Top 10 Players Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share in 2021
- Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
- Figure 44. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Share by Type in 2021
- Figure 45. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share Forecast by Type (2023-2028)
- Figure 46. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Share by Application in 2021
- Figure 47. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share Forecast by Application (2023-2028)
- Figure 48. North America Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Type (2017-2028)
- Figure 49. North America Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Application (2017-2028)
- Figure 50. North America Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Country (2017-2028)
- Figure 51. United States Chemotherapy-induced Nausea and Vomiting Treatment

Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Canada Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Mexico Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Europe Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Type (2017-2028)

Figure 55. Europe Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Application (2017-2028)

Figure 56. Europe Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Country (2017-2028)

Figure 57. Germany Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. France Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. United Kingdom Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Russia Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Italy Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Type (2017-2028)

Figure 63. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Application (2017-2028)

Figure 64. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Region (2017-2028)

Figure 65. China Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Japan Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. South Korea Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. India Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Southeast Asia Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Australia Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. South America Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Type (2017-2028)

Figure 72. South America Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Application (2017-2028)

Figure 73. South America Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Country (2017-2028)

Figure 74. Brazil Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Argentina Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Middle East and Africa Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Type (2017-2028)

Figure 77. Middle East and Africa Chemotherapy-induced Nausea and Vomiting Treatment Sales Market Share by Application (2017-2028)

Figure 78. Middle East and Africa Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Country (2017-2028)

Figure 79. Turkey Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Saudi Arabia Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. UAE Chemotherapy-induced Nausea and Vomiting Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. Methodology

Figure 83. Research Process and Data Source

I would like to order

Product name: Global Chemotherapy-induced Nausea and Vomitting Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Product link: <https://marketpublishers.com/r/G73691F5A5A3EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G73691F5A5A3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

